Infliximab, a TNF-α antagonist, inhibited TNF receptor (TNFR)/nuclear factor κB (NF-κB) signaling and depressive symptoms in MDD patients who were exposed to early life stress [218]. Here, NFKB1 is linked to major depressive disorder.